Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis

Mitesh Shah, Arsh K. Jain, Steven M. Brunelli, Steven G. Coca, Philip J. Devereaux, Matthew T. James, Jin Luo, Amber O. Molnar, Marko Mrkobrada, Neesh Pannu, Chirag Parikh, Michael Paterson, Salimah Shariff, Ron Wald, Michael Walsh, Richard Whitlock, Duminda N. Wijeysundera, Amit X. Garg

Research output: Contribution to journalArticle

Abstract

Background: Some studies but not others suggest angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use prior to major surgery associates with a higher risk of postoperative acute kidney injury (AKI) and death. Methods. We conducted a large population-based retrospective cohort study of patients aged 66 years or older who received major elective surgery in 118 hospitals in Ontario, Canada from 1995 to 2010 (n = 237,208). We grouped the cohort into ACEi/ARB users (n = 101,494) and non-users (n = 135,714) according to whether the patient filled at least one prescription for an ACEi or ARB (or not) in the 120 days prior to surgery. Our study outcomes were acute kidney injury treated with dialysis (AKI-D) within 14 days of surgery and all-cause mortality within 90 days of surgery. Results: After adjusting for potential confounders, preoperative ACEi/ARB use versus non-use was associated with 17% lower risk of post-operative AKI-D (adjusted relative risk (RR): 0.83; 95% confidence interval (CI): 0.71 to 0.98) and 9% lower risk of all-cause mortality (adjusted RR: 0.91; 95% CI: 0.87 to 0.95). Propensity score matched analyses provided similar results. The association between ACEi/ARB and AKI-D was significantly modified by the presence of preoperative chronic kidney disease (CKD) (P value for interaction < 0.001) with the observed association evident only in patients with CKD (CKD - adjusted RR: 0.62; 95% CI: 0.50 to 0.78 versus No CKD: adjusted RR: 1.00; 95% CI: 0.81 to 1.24). Conclusions: In this cohort study, preoperative ACEi/ARB use versus non-use was associated with a lower risk of AKI-D, and the association was primarily evident in patients with CKD. Large, multi-centre randomized trials are needed to inform optimal ACEi/ARB use in the peri-operative setting.

Original languageEnglish (US)
Article number53
JournalBMC Nephrology
Volume15
Issue number1
DOIs
StatePublished - Apr 2 2014

Fingerprint

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Dialysis
Chronic Renal Insufficiency
Acute Kidney Injury
Confidence Intervals
Ambulatory Surgical Procedures
Cohort Studies
Propensity Score
Mortality
Ontario
Canada
Prescriptions
Retrospective Studies
Outcome Assessment (Health Care)
Population

Keywords

  • Acute dialysis
  • Angiotensin converting enzyme inhibitor
  • Angiotensin receptor blocker
  • Major elective surgery

ASJC Scopus subject areas

  • Nephrology

Cite this

Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis. / Shah, Mitesh; Jain, Arsh K.; Brunelli, Steven M.; Coca, Steven G.; Devereaux, Philip J.; James, Matthew T.; Luo, Jin; Molnar, Amber O.; Mrkobrada, Marko; Pannu, Neesh; Parikh, Chirag; Paterson, Michael; Shariff, Salimah; Wald, Ron; Walsh, Michael; Whitlock, Richard; Wijeysundera, Duminda N.; Garg, Amit X.

In: BMC Nephrology, Vol. 15, No. 1, 53, 02.04.2014.

Research output: Contribution to journalArticle

Shah, M, Jain, AK, Brunelli, SM, Coca, SG, Devereaux, PJ, James, MT, Luo, J, Molnar, AO, Mrkobrada, M, Pannu, N, Parikh, C, Paterson, M, Shariff, S, Wald, R, Walsh, M, Whitlock, R, Wijeysundera, DN & Garg, AX 2014, 'Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis', BMC Nephrology, vol. 15, no. 1, 53. https://doi.org/10.1186/1471-2369-15-53
Shah, Mitesh ; Jain, Arsh K. ; Brunelli, Steven M. ; Coca, Steven G. ; Devereaux, Philip J. ; James, Matthew T. ; Luo, Jin ; Molnar, Amber O. ; Mrkobrada, Marko ; Pannu, Neesh ; Parikh, Chirag ; Paterson, Michael ; Shariff, Salimah ; Wald, Ron ; Walsh, Michael ; Whitlock, Richard ; Wijeysundera, Duminda N. ; Garg, Amit X. / Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis. In: BMC Nephrology. 2014 ; Vol. 15, No. 1.
@article{e92a8eba0a11408298b4d34ed85226b8,
title = "Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis",
abstract = "Background: Some studies but not others suggest angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use prior to major surgery associates with a higher risk of postoperative acute kidney injury (AKI) and death. Methods. We conducted a large population-based retrospective cohort study of patients aged 66 years or older who received major elective surgery in 118 hospitals in Ontario, Canada from 1995 to 2010 (n = 237,208). We grouped the cohort into ACEi/ARB users (n = 101,494) and non-users (n = 135,714) according to whether the patient filled at least one prescription for an ACEi or ARB (or not) in the 120 days prior to surgery. Our study outcomes were acute kidney injury treated with dialysis (AKI-D) within 14 days of surgery and all-cause mortality within 90 days of surgery. Results: After adjusting for potential confounders, preoperative ACEi/ARB use versus non-use was associated with 17{\%} lower risk of post-operative AKI-D (adjusted relative risk (RR): 0.83; 95{\%} confidence interval (CI): 0.71 to 0.98) and 9{\%} lower risk of all-cause mortality (adjusted RR: 0.91; 95{\%} CI: 0.87 to 0.95). Propensity score matched analyses provided similar results. The association between ACEi/ARB and AKI-D was significantly modified by the presence of preoperative chronic kidney disease (CKD) (P value for interaction < 0.001) with the observed association evident only in patients with CKD (CKD - adjusted RR: 0.62; 95{\%} CI: 0.50 to 0.78 versus No CKD: adjusted RR: 1.00; 95{\%} CI: 0.81 to 1.24). Conclusions: In this cohort study, preoperative ACEi/ARB use versus non-use was associated with a lower risk of AKI-D, and the association was primarily evident in patients with CKD. Large, multi-centre randomized trials are needed to inform optimal ACEi/ARB use in the peri-operative setting.",
keywords = "Acute dialysis, Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Major elective surgery",
author = "Mitesh Shah and Jain, {Arsh K.} and Brunelli, {Steven M.} and Coca, {Steven G.} and Devereaux, {Philip J.} and James, {Matthew T.} and Jin Luo and Molnar, {Amber O.} and Marko Mrkobrada and Neesh Pannu and Chirag Parikh and Michael Paterson and Salimah Shariff and Ron Wald and Michael Walsh and Richard Whitlock and Wijeysundera, {Duminda N.} and Garg, {Amit X.}",
year = "2014",
month = "4",
day = "2",
doi = "10.1186/1471-2369-15-53",
language = "English (US)",
volume = "15",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis

AU - Shah, Mitesh

AU - Jain, Arsh K.

AU - Brunelli, Steven M.

AU - Coca, Steven G.

AU - Devereaux, Philip J.

AU - James, Matthew T.

AU - Luo, Jin

AU - Molnar, Amber O.

AU - Mrkobrada, Marko

AU - Pannu, Neesh

AU - Parikh, Chirag

AU - Paterson, Michael

AU - Shariff, Salimah

AU - Wald, Ron

AU - Walsh, Michael

AU - Whitlock, Richard

AU - Wijeysundera, Duminda N.

AU - Garg, Amit X.

PY - 2014/4/2

Y1 - 2014/4/2

N2 - Background: Some studies but not others suggest angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use prior to major surgery associates with a higher risk of postoperative acute kidney injury (AKI) and death. Methods. We conducted a large population-based retrospective cohort study of patients aged 66 years or older who received major elective surgery in 118 hospitals in Ontario, Canada from 1995 to 2010 (n = 237,208). We grouped the cohort into ACEi/ARB users (n = 101,494) and non-users (n = 135,714) according to whether the patient filled at least one prescription for an ACEi or ARB (or not) in the 120 days prior to surgery. Our study outcomes were acute kidney injury treated with dialysis (AKI-D) within 14 days of surgery and all-cause mortality within 90 days of surgery. Results: After adjusting for potential confounders, preoperative ACEi/ARB use versus non-use was associated with 17% lower risk of post-operative AKI-D (adjusted relative risk (RR): 0.83; 95% confidence interval (CI): 0.71 to 0.98) and 9% lower risk of all-cause mortality (adjusted RR: 0.91; 95% CI: 0.87 to 0.95). Propensity score matched analyses provided similar results. The association between ACEi/ARB and AKI-D was significantly modified by the presence of preoperative chronic kidney disease (CKD) (P value for interaction < 0.001) with the observed association evident only in patients with CKD (CKD - adjusted RR: 0.62; 95% CI: 0.50 to 0.78 versus No CKD: adjusted RR: 1.00; 95% CI: 0.81 to 1.24). Conclusions: In this cohort study, preoperative ACEi/ARB use versus non-use was associated with a lower risk of AKI-D, and the association was primarily evident in patients with CKD. Large, multi-centre randomized trials are needed to inform optimal ACEi/ARB use in the peri-operative setting.

AB - Background: Some studies but not others suggest angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use prior to major surgery associates with a higher risk of postoperative acute kidney injury (AKI) and death. Methods. We conducted a large population-based retrospective cohort study of patients aged 66 years or older who received major elective surgery in 118 hospitals in Ontario, Canada from 1995 to 2010 (n = 237,208). We grouped the cohort into ACEi/ARB users (n = 101,494) and non-users (n = 135,714) according to whether the patient filled at least one prescription for an ACEi or ARB (or not) in the 120 days prior to surgery. Our study outcomes were acute kidney injury treated with dialysis (AKI-D) within 14 days of surgery and all-cause mortality within 90 days of surgery. Results: After adjusting for potential confounders, preoperative ACEi/ARB use versus non-use was associated with 17% lower risk of post-operative AKI-D (adjusted relative risk (RR): 0.83; 95% confidence interval (CI): 0.71 to 0.98) and 9% lower risk of all-cause mortality (adjusted RR: 0.91; 95% CI: 0.87 to 0.95). Propensity score matched analyses provided similar results. The association between ACEi/ARB and AKI-D was significantly modified by the presence of preoperative chronic kidney disease (CKD) (P value for interaction < 0.001) with the observed association evident only in patients with CKD (CKD - adjusted RR: 0.62; 95% CI: 0.50 to 0.78 versus No CKD: adjusted RR: 1.00; 95% CI: 0.81 to 1.24). Conclusions: In this cohort study, preoperative ACEi/ARB use versus non-use was associated with a lower risk of AKI-D, and the association was primarily evident in patients with CKD. Large, multi-centre randomized trials are needed to inform optimal ACEi/ARB use in the peri-operative setting.

KW - Acute dialysis

KW - Angiotensin converting enzyme inhibitor

KW - Angiotensin receptor blocker

KW - Major elective surgery

UR - http://www.scopus.com/inward/record.url?scp=84898548171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898548171&partnerID=8YFLogxK

U2 - 10.1186/1471-2369-15-53

DO - 10.1186/1471-2369-15-53

M3 - Article

C2 - 24694072

AN - SCOPUS:84898548171

VL - 15

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

IS - 1

M1 - 53

ER -